Image Source: © Ahasoft | Megapixl.com
Highlights
- Australia has received the maiden shipment of Novavax vaccines (Nuvaxovid™), which arrived from Singapore yesterday.
- Novavax is a protein-based vaccine that has been engineered from the genetic material of the SARS-CoV-2 virus.
- It is the fourth vaccine approved for administration in Australia.
In what comes as a new shot in the arm for Australians’ fight against COVID-19, the country received its first shipment of three million Novavax vaccines (Nuvaxovid™) on Monday, which arrived from Singapore. Novavax is the first protein-based COVID-19 vaccine permitted for use in Australia.
Novavax became the fourth vaccine approved for usage in Australia after the Therapeutic Goods Administration (TGA) last month granted provisional approval to Novavax's COVID-19 vaccine Nuvaxovid™ for people aged 18 years and more. After the TGA nod, Australia executed a deal with Novavax to purchase 51 million doses of the vaccine with the option for an extra 10 million doses (61 million doses total).
Do read: ATAGI gives green light to Novavax Covid-19 vaccine
Australia has participated significantly in Novavax’s clinical trials. Further trials for Nuvaxovid booster and a trial for a combination seasonal influenza and COVID-19 vaccine are also in progress in Australia. Approximately 1,500 Australians have played a part in Novavax COVID-19 and combination vaccine clinical trials.
Do read: Australia gets its first protein-based COVID-19 vaccine from Novavax
About Novavax vaccine
Novavax's COVID-19 vaccine Nuvaxovid™ is a protein-based vaccine that has been engineered from the genetic material of the SARS-CoV-2 virus. The vaccine was created using Novavax's recombinant particle technology. The vaccine has an ingredient called Matrix-M adjuvant, which makes a more robust immune response to the vaccine. The vaccine should be administered in two doses with a gap of 21 days.
Also read: Novavax COVID-19 vaccine to hit Australia in January: Greg Hunt
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and